Peking University Third Hospital, Beijing, China (Recruiting) - 31 Dec `25Factors that affect response to ruxolitinib cream

Factors that affect response to ruxolitinib cream

Official title: A Real-world Study on the Influencing Factors of the Efficacy of Ruxolitinib Cream in the Treatment of Vitiligo

Status: Recruiting now

Description:

Peking University Third Hospital plans to enroll about 170 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are studying which patient and treatment factors affect how well ruxolitinib cream works for vitiligo. Participants may complete exams, questionnaires, record reviews, imaging, or sample collection; no drug-related side effects are expected unless they are already receiving routine treatment. People age 12 and older may qualify. The study is recruiting at one listed site in China.

Start date: December 08, 2025

Completion date: December 31, 2027

Organizer: Peking University Third Hospital

Contact: Jinzhu Guo, MD

Tel.: 008 615 611 963 350

Email: guojinzhu_826@163.com

Link: https://clinicaltrials.gov/study/NCT07153666

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Factors that affect response to ruxolitinib cream . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • How Vitiligo Changes with Age?

    Vitiligo, a condition characterized by the loss of skin pigmentation, can affect individuals at any stage of life. While it often appears before the age of 20, its progression a...

  • Can Ayurveda help with vitiligo?

    Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...